Drug Trial Radar · NCT02500381
Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)
Last checked: Nov 20, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
228
Actual
Start
Sep 28, 2016
Primary completion
Nov 12, 2024
Study completion Oct 16, 2025
Sponsor
- Lead sponsor
- Sarepta Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 16, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 6 years, up to 13 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of this study is to evaluate the efficacy of SRP-4045 (casimersen) and SRP-4053 (golodirsen) compared to placebo in participants with DMD with out-of-frame deletion mutations amenable to skipping exon 45 and exon 53, respectively.
Conditions
- Duchenne Muscular Dystrophy
Interventions
SRP-4045Drug
SRP-4045 solution for IV infusion
SRP-4053Drug
SRP-4053 solution for IV infusion
PlaceboDrug
SRP-4045 or SRP-4053 placebo-matching solution for IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the 4-Step Ascend Velocity at Week 96Time frame: Baseline, Week 96
Locations
76 sites in 24 countries. Site status is shown where the registry gives one.
Neuromuscular Research Center
Phoenix, Arizona
Children's Hospital Los Angeles
Los Angeles, California
David Geffen School of Medicine, UCLA
Los Angeles, California
Rady Children's Hospital San Diego/ UCSD
San Diego, California
Stanford University School of Medicine/Medical Center
Stanford, California
University of Florida
Gainesville, Florida
NW Florida Clinical Research Group, LLC
Gulf Breeze, Florida
Center for Integrative Rare Disease Research (CIRDR)
Atlanta, Georgia
Ann and Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
University of Iowa Children's Hospital
Iowa City, Iowa
University of Kansas, Medical Center
Kansas City, Kansas
Boston Children's Hospital
Boston, Massachusetts
St. Louis Children's Hospital
St Louis, Missouri
Las Vegas Clinic
Las Vegas, Nevada
University of Rochester Clinical Research Center
Rochester, New York
Cincinnati Children's Hospital Medical Center (CCHMC)
Cincinnati, Ohio
Nationwide Children's Hospital
Columbus, Ohio
Shriners Hospital for Children
Portland, Oregon
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania
Children's Medical Center Dallas
Dallas, Texas
University of Utah
Salt Lake City, Utah
Children's Hospital of the King's Daughters
Norfolk, Virginia
Children's Hospital of Wisconsin
Milwaukee, Wisconsin
DOM Centro de Reumatologia
Buenos Aires, Argentina
Queensland Children's Hospital
South Brisbane, Australia
Children's Hospital at Westmead
Westmead, Australia
Royal Children's Hospital Melbourne
Parkville, Victoria, Australia
Universitair Ziekenhuis Gent
Ghent, Belgium
Universitair Ziekenhuis Leuven
Leuven, Belgium
CHR de la Citadelle
Liège, Belgium
University Multiprofile Hospital for Active Treatment Aleksandrovska EAD
Sofia, Sofia-Grad, Bulgaria
Alberta Childrens Hospital
Calgary, Alberta, Canada
Children's and Women's Health Centre of British Columbia
Vancouver, British Columbia, Canada
London Health Sciences Centre
London, Ontario, Canada
Children's Hospital of Eastern Ontario
Ottawa, Ontario, Canada
University Hospital Brno
Brno, Czechia
Fakultni nemocnice v Motole
Prague, Czechia
Rigshospitalet Copenhagen University Hospital
København Ø, Denmark
Reference Centre for Neuromuscular Diseases
Nantes, France
Hôpital Armand Trousseau
Paris, France
Showing 40 of 76 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.